NCT04682587View on ClinicalTrials.gov

To Examine the Effects of Axitinib Dose Reduction and Interruption for Adverse Event Management Among Patients Receiving Axitinib in for the Treatment of Advanced Renal Cell Carcinoma

CompletedOBSERVATIONAL
Enrollment

481

Participants

Timeline

Start Date

February 24, 2021

Primary Completion Date

April 5, 2021

Study Completion Date

April 5, 2021

Conditions
Renal Cell Carcinoma
Interventions
DRUG

Axitinib

Inlyta, axitinib

DRUG

Avelumab

Avelumab, Bavencio

DRUG

Pembrolizumab

Pembrolizumab, Keytruda

Trial Locations (1)

10017

Pfizer, New York

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT04682587 - To Examine the Effects of Axitinib Dose Reduction and Interruption for Adverse Event Management Among Patients Receiving Axitinib in for the Treatment of Advanced Renal Cell Carcinoma | Biotech Hunter | Biotech Hunter